Sterility and Bioburden Testing: Two Questions a Purity Certificate Does Not Answer
Ask a US supplier whether their research peptides are sterile and you will usually get a confident yes. Ask what document supports it and the conversation ends, because in almost every case the only document that exists is a chromatographic purity certificate — and a chromatogram says nothing whatsoever about whether anything is growing in the vial.
Sterility and bioburden are not two words for the same idea, and neither of them is purity. They are separate questions, answered by separate compendial procedures, producing separate numbers, and a laboratory that treats them as interchangeable will misread its own material. This article sets out what each test is, what a passing result actually licenses you to conclude, and — the part suppliers skip — where the boundary of our own certificates sits.
Two questions, not one
Sterility is an absolute claim: no viable microorganisms present. It is a binary attribute of a batch, and the compendial procedure that examines it is USP General Chapter <71>.
Bioburden, sometimes called microbial limits, is a count. It asks how many viable organisms are present per gram or per milliliter, and whether any of a defined list of organisms appears at all. The relevant chapters are USP <61> for enumeration, <62> for the specified-organism screens, and <1111> for the acceptance criteria that give those counts meaning.
The distinction matters because it determines which framework a given material belongs under. A lyophilized peptide powder in a stoppered vial is, in compendial terms, a non-sterile article. It is not a finished parenteral product. It has not been through a validated aseptic fill against a sterility assurance target, and nobody in the research-supply chain claims it has. The framework that fits it is microbial limits, not sterility — which makes it striking how often the word “sterile” appears in this category’s marketing and how rarely the word “bioburden” does.
What USP <71> actually involves
The sterility test is more demanding, and slower, than its reputation suggests. Material is introduced into two culture media — Fluid Thioglycollate Medium, incubated at 30–35 °C to recover anaerobes, and Soybean–Casein Digest Medium, incubated at 20–25 °C for aerobes and fungi — and both are held for a minimum of fourteen days with periodic inspection for turbidity.
Material reaches those media by one of two routes. Membrane filtration passes the dissolved article through a filter of 0.45 µm or finer, retaining organisms on the membrane while any antimicrobial component of the article washes through; it is the preferred route wherever the article can be filtered. Direct inoculation adds the article straight to the medium, and is used where filtration is impossible — at the cost of carrying any inhibitory property of the article into the culture with it.
That inhibition problem is why the test cannot simply be run. Method suitability, still widely called the bacteriostasis and fungistasis test, must be established first: the article is spiked with not more than 100 CFU of each of six challenge organisms — Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 9027, Bacillus subtilis ATCC 6633, Clostridium sporogenes ATCC 19404, Candida albicans ATCC 10231 and Aspergillus brasiliensis ATCC 16404 — and growth must appear comparably to an uninhibited control. Without that demonstration, a clear tube proves only that the article suppressed the culture.
Why a passing sterility test is weaker evidence than it sounds
Here is the part that rarely makes it into supplier copy. The sterility test samples a handful of containers from a batch, and the arithmetic of that sample is unforgiving.
Marsit, Saadawi and Alennabi, reviewing growth-based methods in Discover Pharmaceutical Sciences in 2025, put the compendial sampling plan plainly: for a batch of more than 500 units, twenty samples are required, which they describe as far short of what statistical confidence would demand. Run the binomial: if one container in every thousand is contaminated, the probability that a twenty-unit sample catches it is 1 − 0.999²⁰, or about 2 percent. A batch contaminated at 1 percent is detected about 18 percent of the time. A clean sterility result on a batch is consistent with a great deal of contamination.
The same review adds a second failure mode that no amount of sampling fixes: viable but non-culturable organisms. Under stress, bacteria including Burkholderia cepacia, Pseudomonas aeruginosa and Salmonella species shrink and shift metabolically to a state in which they no longer form colonies on medium, while retaining virulence. They are, in the authors’ phrase, undetectable under normal growth conditions. Contaminated units are sometimes identified only after distribution, once organisms adapt to the formulation and proliferate during storage.
This is not an argument for skipping the test. It is an argument for reading it correctly. A sterility result is a confirmation attached to a process that was designed to produce sterility — never the thing that establishes it.
Sterility is built, not tested
FDA’s guidance on sterile drug products produced by aseptic processing makes the same point structurally, by putting almost all of its weight on the process rather than the release test. Its stated purpose for an aseptic process is to prevent any contamination. Knowledge of bioburden, it notes, is important in assessing whether a sterilization process is adequate — bioburden control upstream is what makes the downstream claim credible. Sterilizing filters are specified with a rated pore size of 0.2 µm or smaller, with integrity testing performed post-use. Aseptic process simulations — media fills — carry explicit criteria: on runs of fewer than 5,000 units, no contaminated units should be detected.
Note what that sequence implies for lyophilized material specifically. FDA recommends that media-fill simulations expose unsealed containers to partial evacuation of the chamber in a way that mimics the lyophilization process, and that a partially closed sterile product be transferred only within critical areas. The freeze-drying step is a period during which open containers sit in a chamber, and it is treated as a contamination risk to be simulated and controlled, not as an incidental drying operation.
None of that infrastructure is implied by a purity certificate.
The framework that actually fits a lyophilized powder
For a non-sterile article, the meaningful questions are the microbial-limits ones. USP <61> enumerates the Total Aerobic Microbial Count and the Total Combined Yeasts and Moulds Count on soybean–casein digest agar and Sabouraud dextrose agar. USP <62> screens for specified organisms — Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella, Escherichia coli, bile-tolerant Gram-negative bacteria, Clostridia and Candida albicans.
USP <1111> converts those counts into pass or fail, and it does so by route. Its acceptance table is route-dependent: aqueous oral preparations are held to a TAMC of 10² and a TYMC of 10¹ CFU with E. coli absent, while non-aqueous oral preparations sit at 10³ and 10². Inhalation preparations carry the tightest specified-organism list — P. aeruginosa, S. aureus and bile-tolerant Gram-negative bacteria all absent. The chapter also fixes how the limits are read, and the rule is more permissive than the exponents suggest: 10¹ means a maximum acceptable count of 20, 10² means 200, 10³ means 2000.
A laboratory characterizing research material can borrow that structure directly. Pick the row whose exposure route resembles the intended in vitro or animal-model work, and you have a defensible internal specification — one that is numeric, referenced, and far more informative than an unsupported assertion of sterility.
What our certificates carry, and what they do not
Every batch we release carries a third-party certificate, and every one of those certificates is an identity-and-purity document. The record for BPC-157 10 mg, lyophilized, batch COA on file states 99.41% by HPLC-UV under report DBAV-BPC-10-051226, tested by Testides Analytical, with the fill size stated on the product record and the certificate linked from it.
It does not carry a sterility row. It does not carry a TAMC or TYMC count. It does not carry a specified-organism screen. Saying so is not a disclosure we are cornered into; it is the only way the certificate stays usable, because a document that quietly implies tests it never ran is worse than one that reports a narrower scope honestly.
The operating rule follows from that. If the certificate does not report a microbial attribute, the material was not released against it. A laboratory that needs a bioburden number for its own records commissions the <61>/<62> panel on the lot it holds, against the <1111> row it has chosen, and files the result alongside the purity certificate. That is a few hundred dollars and a week of incubation, and it produces evidence. The alternative — inferring microbial status from a purity percentage — produces nothing but a comfortable assumption.
Ask any US supplier for the sterility or microbial-limits data behind their claims. The answer, whatever it is, tells you more about the operation than the number would have.
References
- Marsit NM, Saadawi S, Alennabi K — challenges of growth-based microbiological methods in sterility assurance of pharmaceutical product manufacturing. Discover Pharmaceutical Sciences, 2025; 1:13. DOI 10.1007/s44395-025-00020-6.
- United States Pharmacopeia, General Chapter <71>, sterility tests — media, incubation conditions, membrane filtration and direct inoculation procedures, and method suitability challenge organisms.
- United States Pharmacopeia, General Chapters <61> and <62>, microbiological examination of non-sterile products — microbial enumeration and tests for specified microorganisms.
- United States Pharmacopeia, General Chapter <1111>, microbiological examination of non-sterile products — acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use. Harmonization document, USP.
- US Food and Drug Administration. Guidance for industry on sterile drug products produced by aseptic processing — current good manufacturing practice. CDER/CBER/ORA, September 2004.
All materials supplied by Maple Research Labs are provided for research use only. They are not for human use, not for veterinary use, and not for diagnostic or therapeutic application. Nothing in this article describes administration to people.